Understanding the Global Pharmacovigilance System

The global pharmacovigilance system is a coordinated network of patient reporters, pharmaceutical company safety teams, national regulators (MHRA, EMA, FDA, PMDA) and the WHO Uppsala Monitoring Centre that detects, evaluates, and acts on adverse drug reactions worldwide. It operates under regulatory frameworks including GVP, ICH E2 guidelines, and country-specific regulations, ensuring medicines remain safe after market approval.

Every medicine on the market — from paracetamol to the most advanced biologic — is being watched. Not by a single regulator, not by a single company, but by a coordinated global system that operates around the clock to detect, evaluate, and act on safety signals as soon as they emerge. That system is called pharmacovigilance, and it is one of the most important and least understood functions in the pharmaceutical industry.

I'm Dorothy Ogwuru, founder of PharmaLink Academy. I started my pharmaceutical career as a pharmacovigilance associate at Novartis and progressed to Global Pharmacovigilance Head before moving into regulatory medical writing. Over 18+ years inside global pharmaceutical organisations, I've seen exactly how the global PV system fits together — and why it matters for patients, regulators, and the healthcare professionals who staff it.

This guide explains the global pharmacovigilance system from the ground up: what it is, how it works, the regulatory frameworks that govern it, and the career roles that keep it running.

What Is Pharmacovigilance, in Plain Terms?

Pharmacovigilance, abbreviated as PV, is the science and practice of detecting, assessing, understanding, and preventing adverse effects of medicines. Where clinical trials test a medicine in carefully selected patients under controlled conditions, pharmacovigilance monitors that medicine in the real world — in millions of patients with co-morbidities, on multiple medications, across different populations, sometimes for decades after approval.

Clinical trials cannot capture every safety risk. Rare adverse events, long-latency effects, drug interactions, and population-specific reactions only emerge once a medicine reaches general use. Pharmacovigilance is the system that catches them.

The work is not optional. Every pharmaceutical company that holds a marketing authorisation in the UK, EU, US, or essentially any developed market is legally required to operate a pharmacovigilance system. Every adverse event must be assessed, classified, and reported within strict regulatory timescales. Failure to do so triggers regulatory action, recalls, fines, and in severe cases the withdrawal of products from the market.

How the Global Pharmacovigilance System Works

The global PV system is best understood as a network of interconnected reporting and analysis layers, not a single centralised body.

At the patient level, an adverse event report originates with a patient, a healthcare professional, a clinical trial site, or a literature publication. That report enters a pharmaceutical company's pharmacovigilance system — or, in some cases, a national regulator's reporting system directly (the MHRA's Yellow Card scheme in the UK is one example).

At the company level, the report is processed by trained PV professionals: triaged for seriousness, coded using medical terminology dictionaries like MedDRA, assessed for causality, narrated, and submitted to relevant regulatory authorities within mandated timelines — typically 7 days for serious unexpected events and 15 days for serious expected events.

At the regulatory level, authorities like the MHRA, EMA, FDA, and PMDA aggregate reports from all market authorisation holders and cross-reference them against existing safety data. This is where signal detection happens: the statistical and clinical analysis that flags emerging safety concerns before they become public health issues.

At the global level, the WHO Uppsala Monitoring Centre coordinates between national pharmacovigilance centres, maintains the VigiBase global database of individual case safety reports, and supports lower-resource countries to build PV capacity. This is what makes the system genuinely global rather than a patchwork of national efforts.

The Regulatory Frameworks That Govern Pharmacovigilance

The global PV system runs on four main regulatory frameworks that any working PV professional needs to understand.

Good Pharmacovigilance Practices (GVP) is the EU framework, published by the European Medicines Agency, that defines how pharmacovigilance should be performed across the EU and EEA. GVP is organised into modules covering everything from pharmacovigilance system master files to risk management plans, signal management, and inspection readiness. Even post-Brexit, the UK's MHRA framework is closely aligned with GVP, so for any PV professional working in the UK pharmaceutical industry, GVP fluency is essential.

ICH E2 guidelines are international harmonisation standards developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E2A through E2F cover everything from clinical safety data management to post-approval safety reporting and pharmacovigilance planning. ICH guidelines are what make pharmacovigilance internationally consistent — the reason a serious adverse event report can be submitted in compatible formats to the MHRA, FDA, EMA, and PMDA without being rebuilt from scratch each time.

MHRA regulations govern pharmacovigilance in the UK specifically. Since Brexit, the MHRA operates as an independent regulator with its own pharmacovigilance requirements that closely mirror but are not identical to GVP. UK PV professionals need to understand the differences — particularly around reporting timelines, the Yellow Card scheme, and post-marketing commitments.

FDA pharmacovigilance requirements cover the United States and operate under the Code of Federal Regulations Title 21. While the underlying principles are the same as GVP and ICH, the FDA has its own reporting structures, FAERS database, and safety communication tools.

Any pharmaceutical company selling globally has to operate within all four frameworks simultaneously. That's why pharmacovigilance roles inside global organisations are in such consistent demand — the regulatory complexity is permanent and growing.

How an Adverse Event Flows Through the System

Walking through a single adverse event illustrates how the global PV system operates day-to-day.

A patient in Manchester reports a serious skin reaction after starting a new medication. They mention it to their GP. The GP submits a Yellow Card report to the MHRA. Simultaneously, the marketing authorisation holder for that medication receives notification of the event — either directly from the patient, the prescriber, or via the regulator.

The PV team at the marketing authorisation holder logs the report into their safety database (commonly Argus or ARISg), assigns a unique case ID, and begins case processing. A PV associate codes the reaction using MedDRA terminology, captures patient demographics and concomitant medications, and drafts a clinical narrative summarising what happened. A more senior PV professional or PV physician assesses causality — was the medicine likely to have caused this reaction? — and seriousness.

If the case meets serious unexpected criteria, a regulatory submission is generated within 7 calendar days. The case is submitted electronically (via E2B XML) to the MHRA, the EMA's EudraVigilance, and the FDA's FAERS in parallel. Each receives the same case in their preferred format.

At the regulatory level, the case is added to the safety database for that medicine. Periodic signal detection algorithms run across the database, looking for disproportionate reporting patterns. If this skin reaction starts appearing in unusual numbers, a safety signal is raised. The marketing authorisation holder is required to investigate, and depending on findings, a label change, dear-doctor letter, or in severe cases a market withdrawal may follow.

This entire cycle — report to assessment to potential regulatory action — is what keeps the global medicines supply safe. It runs constantly, across every approved medicine, in every market.

The Professional Roles Inside a Pharmacovigilance System

Pharmacovigilance employs a range of professionals across operational and scientific tracks.

Operational roles focus on case processing — the day-to-day handling of individual safety reports. Titles include Drug Safety Associate, PV Associate, Safety Case Processor, and PV Officer. UK salaries in operational roles typically run from £25,000 to £50,000 depending on level and complexity.

Scientific roles focus on analysis and decision-making — signal detection, aggregate reporting, risk management plans, and benefit-risk evaluation. Titles include PV Scientist, Drug Safety Scientist, Signal Detection Specialist, and Risk Management Specialist. UK salaries in scientific roles typically run from £35,000 to £60,000.

Senior progression leads to PV Manager, Associate Director of Drug Safety, and ultimately Qualified Person for Pharmacovigilance (QPPV) — the legally accountable individual who oversees an entire company's pharmacovigilance system. QPPV roles command UK salaries of £80,000 to £120,000+.

The work suits people who are detail-oriented, scientifically literate, and comfortable operating in regulated environments. Most successful PV professionals come from healthcare backgrounds — pharmacy, nursing, biomedical science, medicine, or life sciences degrees.

Why the UK Has a Permanent Pharmacovigilance Talent Shortage

Demand for trained PV professionals consistently outstrips supply in the UK, and the gap is structural rather than cyclical.

The pharmaceutical industry faces a documented 35% talent deficit across the sector, and pharmacovigilance is one of the hardest functions to recruit for. Several factors drive this. Volume of safety data is rising sharply as biologics and specialty medicines expand the global drug portfolio. Regulatory expectations are increasing, with risk management plans, periodic benefit-risk evaluation reports, and signal management requirements becoming more demanding. Post-Brexit divergence between MHRA and EMA frameworks has added administrative complexity. And training pathways have not scaled to match demand — UK universities offer short PV courses but few comprehensive career-transition programmes.

For healthcare professionals considering a pivot into pharma, the timing is favourable. The shortage is real, the career trajectory is strong, and the barrier — not having pharmaceutical industry experience — can be bridged through structured training that produces a portfolio of work and gives applicants safety database experience before their first interview.

How to Break Into Pharmacovigilance

If you have a healthcare or life-science background and you're drawn to PV after reading this, the practical question is how to make the transition.

I've written a detailed step-by-step guide on exactly that, focused on the UK career market: How to Get Into Pharmacovigilance: A Step-by-Step Career Guide. It covers what employers actually look for, the salary picture in detail, how to choose between training options, how to handle the safety-database catch-22, and how to position yourself for your first PV role.

PharmaLink Academy's Pharmacovigilance Programme is a six-month structured pathway that takes healthcare professionals from foundation to scientist level — including hands-on case processing, MedDRA coding, signal detection practice, and access to VIGILANT™, our simulated safety database that replicates the workflows of real pharmaceutical PV departments. Explore the programme → or book a call with our team.

The Bottom Line

The global pharmacovigilance system is what makes modern medicine viable. Without it, the safety of medicines after approval would depend on individual reports trickling in to fragmented national systems with no coordination, no signal detection, and no accountability. The system we have today — coordinated through GVP, ICH, MHRA, FDA, and the WHO — took decades to build and is now legally embedded in how medicines are regulated worldwide.

For healthcare professionals, this matters in two ways. First, understanding pharmacovigilance gives you context for how the medicines you prescribe, dispense, or administer are being monitored. Second, the people who run this system are mostly drawn from healthcare backgrounds — and demand for them is rising faster than supply. If you've ever wondered whether the careful, science-led, regulated work that interests you exists outside the clinic, this is one of the answers.

Dorothy Ogwuru is the founder of PharmaLink Academy. Former Global Pharmacovigilance Head. She has 18+ years of experience across pharmacovigilance and regulatory medical writing within global pharmaceutical organisations including Novartis.